IOL Chemicals jumps after receiving CEP for Quetiapine Fumarate

Image
Last Updated : Mar 06 2025 | 10:50 AM IST

IOL Chemicals & Pharmaceuticals rallied 5.48% to Rs 345.65 after the company received a certificate of suitability (CEP) for its API product, Quetiapine Fumarate, from European Directorate for the Quality of Medicines & Health Care (EDQM).

The said certification will enable the company to export Quetiapine Fumarate to European and other countries that accept CEPs. Quetiapine Fumarate is an antipsychotic drug which is widely used to treat various mental health disorders.

IOL Chemicals and Pharmaceuticals is a pharma API and speciality chemicals manufacturer.

The companys consolidated net profit declined 11% to Rs 20.53 crore in Q3 FY25 as compared with Rs 23.08 crore in Q3 FY24. Net sales increased marginally to Rs 523.30 crore in Q3 FY25, up .0.6% as compared with Rs 520.39 crore in Q3 FY24.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 06 2025 | 10:27 AM IST

Next Story